ProstateNext Genetic Test

This genetic test analyzes 14 genes, including the BRCA1 and BRCA2 genes, associated with hereditary cancers.

What is the ProstateNext genetic test?

ProstateNext® is a genetic test that analyzes 14 genes associated with hereditary prostate cancer.

ProstateNext, conducted with a blood or saliva sample, can help men and their healthcare provider:

  • Determine when to start prostate cancer screening tests and how often the tests should be repeated
  • Identify at-risk family members
  • Suggest measures to reduce the patient’s individual risk of developing prostate cancer
  • Tailor treatment to the patient if he develops prostate cancer

Of the 14 genes reviewed in the ProstateNext test are BRCA1 and BRCA2 (known as breast cancer predisposition genes). These genes, when mutated, have been shown to be associated with a 15% lifetime risk of developing prostate cancer, which is significantly higher than the average risk for men without the mutation.

Find the right PC Markers for you. Take quiz.

ProstateNext Video

Learn more about the ProstateNext test, which assesses a patient’s risk for hereditary prostate cancer.

Understanding Your ProstateNext Results

The ProstateNext test is a genetic test that can be effective in determining a person’s risk of developing hereditary prostate cancer. See a sample ProstateNext result report and learn more about how to interpret these results. Please note that all ProstateNext test results should always be discussed with a healthcare provider or genetic counselor first.

ProstateNext FAQs

Below is an initial list of frequently asked questions about the ProstateNext test. You can also submit your question.

1. Why should men consider additional testing beyond the PSA test?

The PSA test cannot differentiate between prostate cancer and non-cancerous (benign) conditions, such as benign prostatic hyperplasia (BPH). Men who receive a PSA level above 1.5 ng/ML should discuss additional biomarker testing with their healthcare providers prior to considering a prostate biopsy.

2. What are prostate cancer biomarkers (PCMs)?

Prostate cancer biomarkers (PCMs) are molecules found in blood, tissue, or body fluids. PCMs are revolutionary new, non-invasive diagnostic tests that may help your healthcare provider decide if your prostate cancer is in fact low risk, if something more aggressive may be lurking in your prostate, or if there are hot spots in the prostate that may need to be re-evaluated upon biopsy. PCMs also can help you and your healthcare provider determine the most appropriate treatment for your cancer.

3. What prostate cancer biomarker test is right for me?

There are many factors that will make one prostate cancer marker test better suited for individual cases. Many times, individuals who have never had a biopsy or had low to intermediate grade prostate cancer (Gleason 3+3=6 or 3+4=7) diagnosed on a biopsy are well suited for blood or urine prostate cancer markers, whereas individuals who have persistently negative biopsies or a biopsy of intermediate to high grade cancer may benefit from tissue prostate cancer markers. Use this interactive questionnaire to see what tests may be right for you.  Once you’ve completed the questionnaire, discuss the results with your healthcare provider. Also be sure to check out our Patient Journey section that may help you decide which test is right for you.

4. Are there any prostate cancer biomarker (PCM) tests that could help me decide if I need to have a prostate biopsy?

Although there are many factors that contribute to your healthcare provider’s decision to conduct a prostate biopsy, there are several urinary and blood based PCMs that may help guide you and your physician through the decision of conducting a prostate biopsy. These include:

Genetic tests also may be worth considering if you have a family history of prostate cancer, breast cancer, ovarian cancer or colorectal cancer. These genetic tests are recommended for men who are determined through genetic counseling to be at potential risk for hereditary cancer:

5. Who should consider a ProstateNext genetic test?

Men with a personal and/or family history of any of the following may benefit from the ProstateNext genetic test:

  • early-onset (<50) of prostate cancer
  • metastatic prostate cancer at any age
  • more than 1 person in their family with prostate, pancreatic, breast or ovarian cancers
  • multiple primary cancers in one person (e.g. prostate and male breast cancer)
  • personal history of prostate cancer and more than 1 family member* with breast cancer (<50 years of age) and/or invasive ovarian cancer
  • personal history of prostate cancer and >2 family members* with breast, pancreatic or prostate cancer

*on the same side of the family

6. What does my ProstateNext genetic test measure?

The ProstateNext test analyzes a blood or saliva sample to provide a full gene sequencing and looks for the deletion/duplication of 14 genes (including BRCA1 and BRCA2).

Test results for ProstateNext are presented in the following fashion (please note that you should always consult with your healthcare provider when reviewing test results):

  • Positive: A mutation was found in at least one of your genes tested. Your risk of developing prostate cancer may be at increased risk compared to others.
  • Negative: No mutations were found in any of your genes tested.
  • Variant of unknown significance (VUS): At least one genetic change was found, but it is not clear if this may lead to an increased risk of cancer.

See a sample ProstateNext test result report and learn more about how to interpret them.